New drug combo targets Post-Transplant cancer in early trial
NCT ID NCT07573436
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a combination of two drugs, loncastuximab tesirine and rituximab, as a first treatment for a rare blood cancer called post-transplant lymphoproliferative disorder (PTLD) that can occur after an organ transplant. The study will first find the safest dose (phase 1) and then check how well the drugs work (phase 2) in 23 adults. The goal is to see if this combination can shrink or eliminate the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
loncastuximab tesirine and rituximab
What this could lead to
If this works, it could offer a new first-line treatment option for post-transplant lymphoproliferative disorder, potentially improving response rates and reducing the need for more toxic therapies.
What could go wrong
This is an early phase 1/2 trial with only 23 participants, so results are preliminary. The combination may cause significant side effects, and it's not yet known if it will be more effective than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••